Table 2.
Change in Outcomes From Baseline by Treatment Group
| Outcome | Time Point | Perindopril | Placebo | Treatment Effect (Perindopril − Placebo) | p |
|---|---|---|---|---|---|
| Change From Baseline | Change From Baseline | ||||
| Mean (SD) | Mean (SD) | Estimate (95% Confidence Interval) | |||
| 6MWD (m) | 10w | 36.7 (63.8) | 23.9 (55.4) | 10.8 (−8.2, 29.9) | 27 |
| 20w | 29.6 (74.9) | 36.4 (59.2) | −8.6 (−30.1, 12.9) | .43 | |
| Quadriceps strength (kg) | 10w | 2.7 (12.5) | 3.9 (14.0) | −1.7 (−5.2, 1.9) | .35 |
| 20w | 0.1 (12.5) | 2.0 (14.8) | −2.1 (−5.5, 1.2) | .21 | |
| Grip strength (kg) | 10w | 0.6 (3.3) | 1.1 (4.6) | −0.5 (−1.7, 0.6) | .34 |
| 20w | 1.0 (3.5) | 1.0 (5.2) | 0.1 (−1.3, 1.4) | .94 | |
| EQ-5D | 10w | 0.07 (0.23) | 0.06 (0.20) | 0.01 (−0.05, 0.07) | .69 |
| 20w | 0.05 (0.25) | 0.05 (0.22) | 0.00 (−0.06, 0.06) | .96 | |
| EQ-5D VAS | 10w | 5.5 (13.5) | 1.9 (14.4) | 3.1 (−0.8, 7.1) | .12 |
| 20w | 1.2 (14.7) | 1.9 (14.8) | −1.3 (−5.7, 3.1) | .56 | |
| SPPB total score | 10w | 1.4 (1.6) | 1.2 (1.7) | 0.1 (−0.4, 0.7) | .58 |
| 20w | 1.0 (2.2) | 1.1 (2.0) | −0.1 (−0.7, 0.6) | .79 | |
| FLP score* | 10w | −80.4 (130.1) | −84.6 (144.2) | 1.8 (−41.1, 44.8) | .93 |
| 20w | −65.7 (157.6) | −68.2 (149.3) | 3.2 (−45.3, 51.6) | .90 |
Notes: 6MWD = 6-minute walk distance); EQ-5D = EuroQol 5D; EQ-VAS = EuroQol Visual Analogue Scale; FLP = Functional Limitation Profile; SPPB = Short Physical Performance Battery.
*Lower values indicate improvement.